ROCKVILLE, Md., Jan. 6, 2021 /PRNewswire/ -- REGENXBIO Inc.
(Nasdaq:RGNX), a leading clinical-stage biotechnology company
seeking to improve lives through the curative potential of gene
therapy based on its proprietary NAV® Technology Platform, today
announced that it intends to offer and sell, subject to market
conditions, $175,000,000 of its
common stock in an underwritten public offering. The offering is
subject to market and other conditions, and there can be no
assurance as to whether or when the offering may be completed, or
the actual size or terms of the offering. In addition, REGENXBIO
intends to grant the underwriters a 30-day option to purchase up to
an additional 15% of the number of common shares sold in connection
with the offering.
BofA Securities, Morgan Stanley and Barclays are acting as joint
book-running managers of the offering.
The securities described above are being offered by REGENXBIO
pursuant to a shelf registration statement on Form S-3 that was
filed with the Securities and Exchange Commission (the "SEC") on
August 8, 2018 (File No. 333-226691)
and became automatically effective upon filing. A preliminary
prospectus supplement relating to and describing the terms of the
offering will be filed with the SEC and will be available on the
SEC's website at www.sec.gov. Copies of the preliminary prospectus
supplement and the accompanying prospectus relating to this
offering, when available, may be obtained from: BofA Securities at
NC1-004-03-43, 200 North College Street, 3rd floor, Charlotte, NC 28255-0001, Attention:
Prospectus Department or by email at
dg.prospectus_requests@baml.com; Morgan Stanley at Attention:
Prospectus Department, 180 Varick Street, 2nd Floor, New York, NY, 10014; or Barclays Capital Inc.,
c/o Broadridge Financial Solutions, at 1155 Long Island Avenue,
Edgewood, New York 11717 or by
email at barclaysprospectus@broadridge.com.
This press release shall not constitute an offer to sell or a
solicitation of an offer to buy any of these securities, nor shall
there be any sale of these securities in any state or jurisdiction
in which such offer, solicitation or sale would be unlawful prior
to registration or qualification under the applicable securities
laws of such state or jurisdiction.
About REGENXBIO
REGENXBIO is a leading clinical-stage biotechnology company
seeking to improve lives through the curative potential of gene
therapy. REGENXBIO's NAV Technology Platform, a proprietary
adeno-associated virus (AAV) gene delivery platform, consists of
exclusive rights to more than 100 novel AAV vectors, including
AAV7, AAV8, AAV9 and AAVrh10. REGENXBIO and its third-party NAV
Technology Platform Licensees are applying the NAV Technology
Platform in the development of a broad pipeline of candidates in
multiple therapeutic areas.
Forward-Looking Statements
This press release includes "forward-looking statements," within
the meaning of Section 27A of the Securities Act of 1933, as
amended, and Section 21E of the Securities Exchange Act of 1934, as
amended. These statements express a belief, expectation or
intention and are generally accompanied by words that convey
projected future events or outcomes such as "believe," "may,"
"will," "estimate," "continue," "anticipate," "assume," "design,"
"intend," "expect," "could," "plan," "potential," "predict,"
"seek," "should," "would" or by variations of such words or by
similar expressions. The forward-looking statements include
statements relating to, among other things, REGENXBIO's proposed
offering of its common stock. REGENXBIO has based these
forward-looking statements on its current expectations and
assumptions as well as other factors REGENXBIO believes are
appropriate under the circumstances. However, whether actual
results and developments will conform with REGENXBIO's expectations
and predictions is subject to a number of risks and uncertainties,
many of which are beyond the control of REGENXBIO. For a discussion
of these risks, refer to the "Risk Factors" and "Management's
Discussion and Analysis of Financial Condition and Results of
Operations" sections of REGENXBIO's Annual Report on Form 10-K for
the year ended December 31, 2019 and
Quarterly Report on Form 10-Q for the quarter ended September 30, 2020 and other filings with the
SEC, which are available on the SEC's website at www.sec.gov. All
of the forward-looking statements made in this press release are
expressly qualified by the cautionary statements contained or
referred to herein. The actual results or developments anticipated
may not be realized or, even if substantially realized, may not
have the expected consequences to or effects on REGENXBIO or its
businesses or operations. Such statements are not guarantees of
future performance and actual results or developments may differ
materially from those projected in the forward-looking statements.
Readers are cautioned not to rely too heavily on the
forward-looking statements contained in this press release. These
forward-looking statements speak only as of the date of this press
release. Except as required by law, REGENXBIO does not undertake
any obligation, and specifically declines any obligation, to update
or revise any forward-looking statements, whether as a result of
new information, future events or otherwise.
Contacts:
Tricia Truehart
Investor Relations and Corporate Communications
347-926-7709
ttruehart@regenxbio.com
Investors:
Eleanor Barisser, 212-600-1902
eleanor@argotpartners.com
Media:
David Rosen, 212-600-1902
david.rosen@argotpartners.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/regenxbio-announces-proposed-public-offering-of-common-stock-301202287.html
SOURCE REGENXBIO Inc.